tbuckley/cabot-search huggingface dataset:
Quantitation of 6, 8 and 10-gingerols and 6-shogaol in plasma by high-performance liquid chromatography
Authors: Suzanna Zick, Zora Djuric, Mack Ruffin, Dean Brenner
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

4990 

Study Purpose: The ginger root or rhizome ( Zingiber officinale Roscoe, Zingiberaceae) is one of the most heavily consumed dietary substances in the world. Research has shown that ginger may prevent cancer and other chronic diseases most likely through anti-inflammatory and antioxidant properties. The purpose of this study was to develop and validate an HPLC assay to detect the main pungent ginger constituents (polyphenols made up of gingerols, shogaols, paradols and zingerone) that are most likely responsible for ginger root’s anti-inflammatory properties, in human plasma.

Methods: A method was developed to extract 6, 8 and 10-gingerols and 6-shogaol from 0.5 mL plasma samples with 50% ethyl acetate and 50% hexane (v/v) and pelargonic acid vanillylamide (PAV), a synthetic capsaicin, as the internal standard. Analysis was achieved using a reversed-phase C18 column with UV detection at 282 nm and electrochemical detection at 500, 550 and 600 µV.

Results: The method demonstrated linear performance from 0.05 to 5.0 µg/mL for all 4 ginger analytes in plasma. The coefficients of variation for intra- and inter-assays were ≤ 19.5% for 6-gingerol, ≤ 18.1% for 8-gingerol, ≤ 32.4% for 10-gingerol and ≤ 28.7% for 6-shogaol. The average recovery of 6-gingerol was > 81.3%, for 8-gingerol < 76.4%, for 10-gingerol < 98.2% and for 6-shogaol was < 73.5%.

Conclusions: This method provides a rapid and sensitive method for detecting 6, 8 and 10-gingerols and 6-shogaol in plasma.
Patients providing the answers: narrowing the gap in data quality for emergency care
Authors: Stephen Calder Porter, Peter Forbes, Shannon Manzi, Leslie A. Kalish
Journal: BMJ (2010)

Objective The authors examined the validity of documentation produced during paediatric emergency care to determine if a patient-driven health information technology called ParentLink produced higher-quality data than documentation completed by nurses and physicians. Design The authors analysed the quality of information across elements of allergies to medications and the history of present illness (HPI) collected during a quasiexperimental intervention study where control periods with usual care alternated with intervention periods when ParentLink was operational. Documentation by emergency department (ED) providers was abstracted and compared with information generated through ParentLink. The criterion standard for the history of allergies to medications was a structured telephone interview with parents after the ED visit. A valid report for a medication allergy was one that was both accurate and complete. Completeness of the HPI for acute head trauma was evaluated across seven elements relevant to an evidence-based risk assessment. Results Of 1410 enrolled parents, 1111/1410 (79%) completed the criterion standard interview. Parents’ valid reports of allergies to medications were higher than those of nurses (parents 94%, nurses 88%, p<0.0001). Parents’ valid reports of allergies to medications were greater than those of physicians (parent 94%, physicians 83%, p<0.0001). ParentLink produced more complete information on HPI for head trauma than the medical record for five of seven elements. Conclusion ParentLink provided electronic information that met or exceeded the quality of data documented by ED nurses and physicians.
Abstract P027: Fasting Glucose And Risk Of Heart Failure
Authors: Hassan Khan, Setor Kunutsor, Jussi Kauhanen, Sudhir Kurl, Eiran Gorodeski, Amanda Adler, Javed Butler, Jari A Laukkanen
Journal: Circulation (2014)

Background: There remains uncertainty regarding the association between fasting glucose (FG) and the risk of heart failure (HF) in individuals without a history of diabetes. Methods and Results: We assessed the association between FG and HF risk in a population-based cohort of 1,740 men aged 42-61 years free from HF or diabetes at baseline. Additionally, we performed a meta-analysis of relevant prospective studies identified from MEDLINE, EMBASE, and Web of Science databases. During a mean follow-up of 20.4 years, 146 participants developed HF (4.1 cases per 1000 person-years). In models adjusted for age, the hazard ratio (HR) for HF per 1 mmol/L increase in FG was 1.34 (95% confidence interval [CI], 1.22, 1.48). This association persisted after adjustment for established HF risk factors (HR 1.27, 95% CI 1.14, 1.42). Compared with FG&lt; 5.6 mmol/L, there was an increased risk amongst those with FG 5.6-6.9 mmol/L (HR 1.24, 95% CI 0.82, 1.88) and ≥ 7.0 mmol/L (HR 3.25, 95% CI 1.50, 7.08). HRs remained consistent across several clinical subgroups. In a meta-analysis of 10 prospective studies (Figure 1) involving a total of 4,213 incident HF cases, the HR for HF per 1 mmol/L increase in FG level was 1.11 (95% CI 1.04, 1.17), consistent with a linear dose-response relationship with evidence of heterogeneity between studies (I2=79%, 63-89%; P&lt;0.001). Conclusions: A positive, continuous, and independent association exists between FG and risk for HF. Further studies are needed to evaluate the causal relevance of these findings.
Diseases of the Liver, Gall-bladder and Bileducts.
Authors: A. G. Nicholls
Journal: Annals of Internal Medicine (1929)

One is prepared to welcome a good book, especially one in English, on diseases of the liver. Budd, Harley and Murchison are out of date; the more recent work of Quincke and Hoppe-Seyler in Nothnagel's series is not entirely satisfactory. Probably books on this subject are not more numerous because there is still so much that is vague and misty in the physiology, pathology, and pathologic chemistry of the liver, and so much that is unsatisfactory in the matter of treatment. But disease of the liver is a something that is real and that has to be reckoned with by every practitioner, and a reliable guide is a necessity; such a guide will be found in Rolleston's work. The book is eminently practical; it is not overbalanced with theory, in fact we may question whether the author has acted wisely in some instances in omitting certain theories. Rolleston's contributions to
184. Evaluation of Cystine Transport in Cultured Human Kidney Cells: Primer to Gene Therapy of Cystinuria
Authors: Sreedhar Sagi, Thomas Knoll, Axel Schaaf, Peter Alken, Maurice Stephan Michel
Journal: Molecular Therapy (2004)

Introduction and objectives: For an efficient gene therapeutical approach, undperstanding the molecular basis of the disease is very important. Cystinuria is a rare hereditary disease resulting in recurrent stone formation and the need for repeated invasive interventions. It is the cause of 1–2% of stones observed in adults and about 10% of those occurring in children. So far, two responsible genes have been identified which encode the transporters rBAT and b0,+AT which form a heterodimer and transport Cystine and Leucine among others and whose defect results in crystallisation of cystine. Understanding the transport efficiency of these amino acids in normal and diseased cells is vital. A human cell line which mimics the phenotype of cystinuria in vitro is yet to be developed.
Manuel de Neurologie Oculaire.
Authors: Félix de Lapersonne, André-Louis Cantonnet
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14944: Elevated Peak Immune Monitoring Early After Transplantation is Associated with Angiographic Cardiac Allograft Vasculopathy
Authors: Richard Cheng, Babak Azarbal, Aaron Yung, Frank Liou, Jignesh K Patel, Jon A Kobashigawa
Journal: Circulation (2014)

Introduction: Early immune monitoring (IM) as measured by adenosine triphosphate release from activated lymphocytes is associated with coronary plaque progression by intravascular ultrasound. Hypothesis: Elevated IM is also associated with angiographic cardiac allograft vasculopathy (CAV). Methods: Patients transplanted between January 2007 and December 2011 with early post-transplant IM assays and annual angiographic follow-up were included. IM score was defined as the peak value of assays performed between two-months to mid-year after transplantation. A receivers operating characteristics (ROC) analysis was performed to determine an optimal IM assay cutoff. International Society of Heart Lung Transplantation CAV grading was used, 1 for mild, 2 for moderate, and 3 for severe. Patients were divided into two groups based on the cutoff score, and freedom from angiographic CAV was compared. Results: 232 patients were included in the analysis. Mean age at transplantation was 56.7 ± 11.8 years and 25.9% were female. Peak IM assays occurred at 104.1 ± 43.7 days after transplantation, with an average of 3.2 ± 1.8 assays measured per patient. A ROC analysis determined an optimal IM assay cutoff of 458 ng ATP/ml. Group 1, n = 178, was defined as having peak IM assays &lt;458 ng ATP/ml. Group 2, n = 54, was defined as having peak IM assays ≥458 ng ATP/ml. Mean peak IM assays for Group 1 and Group 2 were 243.1 ± 115.5 and 592.9 ± 155.5 ng ATP/ml, respectively. Mean clinical and angiographic follow-up were 4.0 ± 1.5 and 3.5 ± 1.6 years, respectively. As demonstrated in Figure 1, CAV1 occurred in 80 of 178 patients (44.9%) in Group 1, and 35 of 54 patients (64.8%) in Group 2, p-value 0.008 (Log Rank). CAV2/3 occurred in 6 of 178 patients (3.4%) in Group 1, and 8 of 54 patients (14.8%) in Group 2, p-value 0.002. Conclusions: Early elevated peak IM is associated with decreased freedom from angiographic CAV and suggests the potential use of IM in the tailoring of immunosuppression regimens for preventing CAV.
Abstract 17484: MG53 Modulates KChIP2 Expression through Regulation of NF-κB Activity
Authors: Wenjuan Liu, Cuicui Zhang, Jianxin Deng, jie liu
Journal: Circulation (2014)

Background:  The fast transient outward K +  current (I to,f ) is an important repolarizing component in heart. I to,f  is formed by specific interaction of the pore-forming Kv4-subunits and obligatory ancillary subunits K +  channel interacting protein 2 (KChIP2). Recent study shows that MG53, a muscle-specific TRIM-family protein is critical for maintaining cardiac electrical stability. In this study, we investigated the possible role of MG53 in regulation of I to,f  activity and the underlying mechanisms.   Methods:  Bidirectional manipulations of MG53 expression were performed by adenoviral overexpression of MG53 or knockdown of MG53 with RNA interference in neonatal and adult rat ventricular myocytes. I to,f  was recorded with patch clamp in whole-cell mode 48 h after adenoviral transfection.   Results:  Overexpression of MG53 by 100% increased the amplitude of I to,f  by 112%, whereas knockdown of MG53 by 58% decreased it by 38% in neonatal cardiomyocytes. MG53 overexpression slowed the kinetics of inactivation and positively shifted the voltage-dependent inactivation of I to,f , while knockdown of MG53 contrarily regulated these properties. Consistent with the alterations in I to,f  magnitude, overexpression of MG53 increased the protein levels of KChIP2 by 245%, whereas knockdown of MG53 expression decreased it by 42%. However, neither overexpression nor knockdown of MG53 affected the protein levels of Kv4.2 and Kv4.3. Bidirectional manipulations of MG53 had similar effects in adult cardiomyocytes as those in neonatal cardiomyocytes, except that overexpression of MG53 had less effects on increasing KChIP2 expression and I to,f  magnitude. Biochemical assays showed that overexpression of MG53 decreased nuclear factor (NF)-κB importing into nuclear, whereas knockdown of MG53 increased NF-κB nuclear translocation. Overexpression of NF-κB activator IκB kinase-β inhibited the stimulation effects of MG53 overexpression on the protein expression of KChIP2. Concomitantly, overexpression of NF-κB inhibitor IκBαSA inhibited the suppression effects of MG53 knockdown on KChIP2 expression.   Conclusion:  These findings establish MG53 as a novel endogenous regulator of KChIP2 expression and I to,f  activity in heart by modulating NF-κB signaling.
Inhibition of constitutively activated Src and STAT3 in small cell lung cancer (SCLC) results in growth inhibition.
Authors: Tania Cortas, Amy Kluge, David Nethery, Jeffrey Kern, Afshin Dowlati
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

5514 

Activation of protein tyrosine kinases is prevalent in human cancers. Many studies have demonstrated that STAT3 signaling is a common downstream signaling protein for receptor as well as non-receptor tyrosine kinases. Unlike non-small cell lung cancer, the role of STAT3 signaling is unknown in SCLC. To elucidate this role we determined STAT3 expression and activation status (p-STAT3) in SCLC cell lines. The SCLC cell line H889 was grown in RPMI media with and without 10% FBS. Under serum-free conditions, significant constitutive activation of STAT3 (p-STAT3) was observed by western blotting. Known growth promoting ligands for SCLC, including hepatocyte growth factor (HGF) and insulin growth factor (IGF) failed to increase STAT3 phosphorylation above its constitutive base line activation at all doses tested or at early and late time points after exposure.. Investigating non-receptor tyrosine kinases that might activate STAT3, we found constitutive activation of Src (p-Src) in H889 cells also. SU6656, a specific inhibitor of Src kinase,caused a simultaneous and proportional decrease in Src as well as STAT3 phosphorylation. The decrease in Src and STAT3 activation was SU6656 dose dependent with complete disappearance of p-Src and p-STAT3 at 3μM. This was associated with dose dependent growth inhibition of the H889 cell line with SU6656. At a SU6656 concentration of 0.3μM 50% growth inhibition was seen at 48 hours. Our study demonstrates that in SCLC, STAT3 is constitutively activated. Src activation is responsible for STAT3 activation, not receptor tyrosine kinases. Src inhibition has significant anti-proliferative effects.
Soluble liver h proteins during hepatocarcinogenesis by aminoazo dyes and 2-acetylaminofluorene in the rat.
Authors: Sam Sorof, Emily M. Young, Marilyn G. Ott
Journal: Cancer Research (1958)

Summary  1.The soluble h proteins of rat liver have been electrophoretically resolved into six sub-components.  2.The proteins of two sub-components, h 2  and slow-h 2 , contain in all cases bound dyes after the feeding of any of the following aminoazo dyes: the carcinogenic 4-dimethylaminoazobenzene (DAB) for   $\rm 4{1\over2}$   and 11 weeks; the more potent carcinogen, 3′-methyl-DAB, for   $\rm 2{1\over2}-3$   weeks; the very weakly carcinogenic 4′-methyl-DAB for 11 weeks; and the noncarcinogenic 2-methyl-DAB for   $\rm 4{1\over2}$   and 11 weeks.  3.The h 3  and slow-h 2  proteins, after the feeding of the control or 3′-methyl-DAB diet for   $\rm 2{1\over2}-3$   weeks, do not contain tightly bound flavin, ribonucleic acid, or deoxyribonucleic acid.  4.Each azocarcinogen of this restricted series produced a significant increase in the amount of the slow-h 2  proteins. In contrast, the azo noncarcinogen, 2-methyl-DAB, did not induce this response, despite the analogous production of dyes bound to these proteins. The feeding of the hepatocarcinogen, 2-acetylaminofluorene, for 5 weeks more than doubled the amount of slow-h 2  proteins, while results with the feeding of ethionine for   $\rm 8{1\over2}$   weeks were inconclusive. Liver regeneration, dye toxicity, and decreased food intake, per se, did not appear to be causally involved in this response of the slow-h 2  proteins. Regarding aminoazo dye carcinogenesis, the increase in the amount of slow-h 2  proteins appeared to correlate with the protein-binding of carcinogenic azo metabolites.  5.The possible implications of these findings to the protein deletion hypothesis of aminoazo dye carcinogenesis are discussed.
Intracostal neuralgia as a previously undescribed symptom of Schnitzler’s syndrome
Authors: K.Y.C. Lee, C.E.H. Grattan
Journal: British Journal of Dermatology (2012)

Journal Article Intracostal neuralgia as a previously undescribed symptom of Schnitzler's syndrome Get access K.Y.C. Lee, K.Y.C. Lee Department of Dermatology, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, U.K. E‐mail: clive.grattan@nnuh.nhs.uk Search for other works by this author on: Oxford Academic Google Scholar C.E.H. Grattan C.E.H. Grattan Department of Dermatology, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, U.K. E‐mail: clive.grattan@nnuh.nhs.uk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 167, Issue 6, 1 December 2012, Pages 1392–1393, https://doi.org/10.1111/j.1365-2133.2012.11057.x Published: 01 December 2012
Taking a history
Authors: Rajendra Kale
Journal: BMJ (2001)

Doctors always have a story to tell about how they made a brilliant diagnosis from the history alone. The patient is usually someone seen earlier by a rival doctor who failed to make the correct diagnosis, despite having all possible investigations to hand. It is usually an “I am so clever” story, but Matthew Bull (p 1339) has an honest and courageous story to tell. He recounts how he …
Delayed Organic Diseases of the Nervous System Following Traumatism and the Question of Appraisal of Disability for Compensation
Authors: Alfred Gordon
Journal: Annals of Internal Medicine (1931)

Article1 April 1931Delayed Organic Diseases of the Nervous System Following Traumatism and the Question of Appraisal of Disability for CompensationALFRED GORDONALFRED GORDONSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-4-10-1313 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn traumatic affections of the nervous system two possibilities are considered: one when they follow the accident immediately and consist of a damage to the cellular tissue or to the projection and association tracts with the result of immediate cessation of function of the parts depending on those nervous elements. The other possibility is when a certain more or less considerable interval passes between the date of the accident and the appearance of the disturbed function in the body. The first occurrence does not require any special emphasis, as the relation between the trauma and sensorimotor manifestations is very evident.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia*Read at the June meeting of the American Neurological Association in Atlantic City. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie traumatischen Erkrankungen des Gehirns und Rückenmarks 1 April 1931Volume 4, Issue 10Page: 1313-1318KeywordsDisabilitiesNervous system ePublished: 1 December 2008 Issue Published: 1 April 1931 PDF downloadLoading ...
Mr.-Guided Cardiac Interventions Using Mr.-Safe Passive Devices: A Preclinical Study and First-in-Man Congenital Interventions
Authors: A. Tzifa, G.A. Krombach, N. Kraemer, S. Krueger, A. Schuette, M. Von Walter, T. Schaeffter, S. Qureshi, T. Krasemann, E. Rosenthal, C. Schwartz, G. Varma, A. Buhl, A. Kohlmeier, A. Buecker, R.W. Guenther, R. Razavi
Journal: Circulation (2011)

Background: Percutaneous cardiac interventions are currently performed under X-ray guidance. Magnetic resonance imaging has been employed to guide intravascular interventions in the past, but mainly in animals. Translation of MR-guided interventions into humans has been limited by the lack of fully MR-compatible and safe devices, such as MR guidewires with mechanical characteristics similar to standard guidewires. The aim of the present study was to evaluate the safety and efficacy of a newly developed MR-safe and compatible passive guidewire in aiding MR-guided cardiac interventions in a swine model and describe the two first-in-man solely MR-guided interventions.
Methods and Results: In the preclinical trial, the new MR compatible wire aided the performance of 20 interventions in 5 swine. These consisted of balloon dilation of nondiseased pulmonary and aortic valves, aortic arch and branch pulmonary arteries. Catheter manipulations were monitored with real time MRI sequence with interactive modification of imaging plane and slice position. Following ethics and regulatory authority approval the two first-in-man MR-guided interventions were performed in a child and an adult, both with elements of valvar pulmonary stenosis. Both patients had successful relief of the valvar stenosis and were discharged home a few hours later with no complications.
Conclusions: The described pre-clinical study and case reports are encouraging that with the availability of the new MR compatible and safe guidewire, certain percutaneous cardiac interventions will become feasible to perform solely under MR-guidance. The benefits are clear with elimination of the use of ionising radiation and improvement of visualisation of the target lesions.